Bought-and-paid-for optionality: the company already holds a second, unmonetized position it can switch on at will
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO based on transcript. Need identify if management describes a second, largely unmonetized position already in hand, future use within company's control, actively deciding how/when to convert. Let's parse. Company Alkermes. Current business: VIVITROL, ARISTADA, manufacturing/royalty revenues (RISPERDAL CONSTA, INVEGA, AMPYRA), R&D collaborations. Pipeline: ALKS 5461 (pending FDA, AdCom), ALKS 3831 (Phase III data), BIIB098 (diroximel fumarate with Biogen, NDA submission by year-end), ALKS 4230 (immuno-oncology). Also "internal research and discovery efforts and expanding capabilities in biologics." Question asks: Does management describe that company ALREADY POSSESSES A SECOND, LARGELY UNMONETIZED POSITION — something real it holds today, beyond business currently producing results — whose future use is largely within company's own control to switch on, and management conveys actively deciding how and when to turn that holding into revenue, rather than whether ever able? Need see if any holding fits. Potential candidates: - BIIB098/diroximel fumarate: developed with Biogen, NDA submission by year-end, Biogen commercial launch. But it's not yet approved, not in hand? It's a product in development, not currently producing revenue. Management says "we continue to make great progress and we're on track to submit the NDA by year-end. This would position Biogen for potential commercial launch in early 2020." That's future, contingent on approval, not already holding. Not unmonetized position already in hand. - ALKS 4230: novel immuno-oncology candidate, in clinical trials. Not approved, not monetized. Not in hand as revenue-generating. - ALKS 5461, 3831: pipeline, not approved. - Maybe "internal research and discovery efforts and expanding capabilities in biologics" - not a holding. - Maybe "long-acting injectable" expertise? Not a separate holding. - Maybe "ARISTADA INITIO" launch? Already being monetized. - Maybe "VIVITROL" growth? Already monetized. - Maybe "manufacturing and royalty business" includes AMPYRA, but generic competition. Not dormant. - Maybe "our diverse portfolio of late stage assets" - but those are not yet monetized, and conversion depends on FDA approvals, data readouts, not solely company's control. So no. - Maybe "we have a resilient and diverse business and many opportunities for growth" generic.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| FCX | Freeport-McMoRan Inc. | Q3 2017 | 2017-10-25 | D |
CLMT · Q1 2018 → YESThe question is about whether management describes an already possessed second, largely unmonetized position that they can switch on themselves. YES The transcript shows management describing the Biosynthetic Technologies acquisition as a real holding already in hand (completed Q1 2018, with 71 issued patents, 76 pending, exclusive USDA license), separate from the operations generating current results. It contributes little today (only $4M acquisition expenses noted, no revenue yet), and management is actively deciding how and when to monetize it—via low-capex proof-of-concept at the Missouri esters plant, new product innovation center, and third-party involvement—within their control. This fits the criteria as a dormant capability they are now sequencing for revenue.
LEGH · Q4 2023 → YESThe question is about whether management describes a second, largely unmonetized position that the company already possesses, whose future use is largely within their control, and they're actively dec...YES The transcript shows management describing land holdings as a second, largely unmonetized position separate from current operations. They hired a dedicated team to prioritize and accelerate land development, with Del Val Bastrop County as the top priority, and note capital is accelerating for this project.
FCX · Q3 2017 → YESThe question is about whether management describes a second, largely unmonetized position that they already possess, whose future use is within their control, and they're actively deciding how and whe...YES The transcript shows management describing exactly this situation: the company already owns large undeveloped sulfide resources (Lone Star oxide/sulfide, El Abra sulfide, Kisanfu cobalt, additional Grasberg material) that are not part of current production and contribute little to today's results.